SGD Pharma, a global provider of pharmaceutical glass primary packaging solutions, entered a strategic collaboration with Prince Sterilization Services, LLC to validate Ready-to-Use (RTU) Type I glass primary packaging solutions for the North American market. 

As a result of this collaboration the My Sterinity Nasal platform is launching. It’s a new flexible cleaned vial range within SGD Pharma’s My Sterinity RTU platform using the company’s U-Save Type I vials which are designed to support the expanding segment of high-value nasal drug delivery. The launch will be showcased at DCAT Week 2026.

My Sterinity Nasal platform combines SGD Pharma’s leadership in Type I glass manufacture and Prince’s expertise in sterilization services. Initially available in 3.5ml, 7.5ml and 10ml formats in both clear and amber glass, My Sterinity Nasal vials offer key benefits for high-value nasal therapies:

                  •               Controlled particulate and endotoxin levels for enhanced purity

                  •               Biologically inert Type I sterile glass, with no need for preservatives

                  •               Validated Sterility assurance

                  •               Compatibility with standard nasal preservative free pump systems

                  •               Packaged in double-bagged trays for RTU presentation. 

My Sterinity Nasal vials support sensitive nasal drug delivery by using high-quality primary packaging, which protects the drug and ensures its stability, safety and efficacy. Production of the My Sterinity Nasal range will take place at SGD Pharma’s Saint-Quentin-La-Motte (SQLM) manufacturing facility in northern France, while Prince will provide washing, depyrogenation and sterilization services in North America, ensuring a validated, regional supply chain qualified for U.S. biopharmaceutical customers.

Historically dominated by plastic, glass for the nasal market offers greater chemical inertness, barrier protection and long-term biocompatibility, which is critical for preserving product integrity, minimizing adsorption and ensuring sterility in chronic-use therapies. The nasal market is expanding with more advanced and long-term treatments such as Alzheimer’s, Parkinson’s, multiple sclerosis and depression, that required a primary packaging combining sterility, consistency, and precision dosing, making Type I glass the material of choice to safeguard long-term therapeutic stability.

Carole Grassi, Chief Commercial Marketing & Innovation Officer, SGD Pharma said, “Our collaboration with Prince marks an important milestone in SGD Pharma’s innovation growth strategy for North America. The My Sterinity Nasal platform represents a major step forward in high-value nasal drug delivery, and our collaboration with Prince unlocks immediate US-qualified capacity for biopharma customers scaling complex nasal therapy programs. This is more than a product launch, it is a validated supply chain ready to support qualification, clinical trials and commercial launch with unmatched speed and reliability.”

Daniel Prince, Ph.D., CEO of Prince added: “SGD Pharma’s Type I glass expertise combined with our quality focused and flexible RTU & sterilization platform creates the gold standard for sterile nasal packaging. Prince’s recent US qualification means we can now deliver ready-to-use, terminally sterilized My Sterinity Nasal vials in timelines that match domestic and international customer development cycles and exceed quality requirements.”